{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:56:10Z","timestamp":1765727770354},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T00:00:00Z","timestamp":1375056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070111","type":"journal-article","created":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T17:12:43Z","timestamp":1375117963000},"page":"e70111","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1371","volume":"8","author":[{"given":"Yukai","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/01.HYP.0000165020.14745.79","article-title":"Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome","volume":"45","author":"JG Wang","year":"2005","journal-title":"Hypertension"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005344-199509000-00018","article-title":"Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial","volume":"26","author":"RA Kloner","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"M Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"10A","DOI":"10.1016\/j.amjcard.2009.10.006","article-title":"Progression of cardiovascular damage: the role of renin-angiotensin system blockade","volume":"105","author":"JL Probstfield","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd873","article-title":"Drugs targeting the renin-angiotensin-aldosterone system","volume":"1","author":"MA Zaman","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"J Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/jhh.2008.162","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review","volume":"23","author":"VM Musini","year":"2009","journal-title":"J Hum Hypertens"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"A Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":"Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial","volume":"26","author":"K Andersen","year":"2008","journal-title":"J Hypertens"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"S Oparil","year":"2007","journal-title":"Lancet"},{"key":"ref11","unstructured":"Higgins J, Green S (2011) Cochrane handbook for systematic reviews of intervensions. 5.1.0. The Cochrane Collaboration."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension","volume":"25","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-6175.2007.06614.x","article-title":"Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy","volume":"9","author":"W Drummond","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref14","first-page":"489","article-title":"Comparative efficacy and safety of combination aliskiren\/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome","volume":"5","author":"MH Weinberger","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1742-1241.2012.02967.x","article-title":"Treatment with aliskiren\/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial","volume":"66","author":"RC Braun-Dullaeus","year":"2012","journal-title":"Int J Clin Pract"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, et al. (2012) Antihypertensive Efficacy and Tolerability of Aliskiren\/Amlodipine Single-Pill Combinations in Patients with an Inadequate Response to Aliskiren Monotherapy. Curr Vasc Pharmacol.","DOI":"10.2174\/157016112803520765"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial","volume":"377","author":"MJ Brown","year":"2011","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pfeiffer D, Rennie N, Papst CC, Zhang J (2012) Efficacy and Tolerability of Aliskiren\/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy. Curr Vasc Pharmacol.","DOI":"10.2174\/157016112803520945"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Littlejohn TW 3rd, Jones SW, Zhang J, Hsu H, Keefe DL (2012) Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens.","DOI":"10.1038\/jhh.2012.42"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","article-title":"Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption","volume":"15","author":"M Azizi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199002000-00015","article-title":"Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition","volume":"15","author":"V Mooser","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"AH Gradman","year":"2005","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/HJH.0b013e3280104dba","article-title":"Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity","volume":"25","author":"M Lindqvist","year":"2007","journal-title":"J Hypertens"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00004872-200206000-00026","article-title":"Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects","volume":"20","author":"J Struck","year":"2002","journal-title":"J Hypertens"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.hjh.0000170389.69202.53","article-title":"Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients","volume":"23","author":"M Karas","year":"2005","journal-title":"J Hypertens"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.bjp.0704753","article-title":"Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism","volume":"136","author":"B Xu","year":"2002","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.amjhyper.2004.05.025","article-title":"Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension","volume":"17","author":"M Kato","year":"2004","journal-title":"Am J Hypertens"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/01.HYP.37.3.943","article-title":"Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension","volume":"37","author":"S Taddei","year":"2001","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/HYPERTENSIONAHA.108.111120","article-title":"Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes","volume":"52","author":"T Imanishi","year":"2008","journal-title":"Hypertension"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"JC6","DOI":"10.7326\/0003-4819-156-12-201206190-02009","article-title":"ACP Journal Club. Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone","volume":"156","author":"L Moist","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jash.2012.09.001","article-title":"Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity","volume":"6","author":"J Kato","year":"2012","journal-title":"J Am Soc Hypertens"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T18:53:06Z","timestamp":1563562386000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070111"}},"subtitle":[],"editor":[{"given":"Dermot","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,29]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070111","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,29]]}}}